drugset
drugset / Trial / NCT05481333

A Trial to Learn if REGN7999 is Safe and Well Tolerated, and How it Works in the Body of Healthy Participants

NCT05481333 ↗

Phase 1 Completed 64 enrolled Regeneron Pharmaceuticals
RandomizedSequentialQuadruple-blindTreatment

Summary

The primary objective of the study is to evaluate the safety and tolerability of single ascending intravenous (IV) and subcutaneous (SC) doses of REGN7999 in healthy adult participants. The secondary objectives of the study are: * To characterize the drug concentration profile of single doses of IV or SC REGN7999 * To assess the immunogenicity of single ascending SC or IV doses of REGN7999

Timeline

Start
2022-10-24
Primary completion
2023-08-29
Completion
2023-08-29

Drugs

EvaluationDrugModalityDoseRoute
Subject REGN7999 Unknown — Intravenous

Indications

No indication recorded.